NCT01798368已完成1 期
An Open Label Study to Evaluate the Safety and Tolerability of Nasal Stimulation Using the PBASE System in Non-patient Volunteers
Chordate Medical0 个研究点目标入组 12 人开始时间: 2013年1月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 12
- 主要终点
- Change in ECG variables
研究概览
简要总结
The purpose of this study is to demonstrate that the treatment does not cause any clinically significant effects that would put patients at risk.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent prior to participation in the clinical investigation
- •Judged by the Investigator as suitable for participation in the study without safety concerns based on medical history, physical examination and laboratory results
- •Age: 18-65 years of age.
- •Gender: Male or female subjects.
- •Negative urine drug screen (amphetamine, benzodiazepines, cocaine, marijuana, metamphetamine, morphine) at screening and Visit
- •Female subjects have to be post-menopausal for more than one year or use a highly efficient method of contraception (i.e. a method with less than 1% failure rate [e.g. sterilisation, hormone implants, hormone injections, some intrauterine devices, abstinence, or vasectomised partner]). Oral contraceptives: combined pill (estrogen / progestin) and medium-dose progestin pill (for example desogestrel 75ug) are accepted only in combination with the partner using condoms.
- •Willing and able to comply with all study procedures and restrictions
排除标准
- •A diagnosis of asthma or chronic obstructive pulmonary disorder.
- •Ongoing respiratory infection including the nasal cavity.
- •Current malignancy of any kind.
- •History of frequent nose bleeds or a condition that increases the risk of excessive bleeding.
- •Pronounced anterior septal deviation or other significant nasal pathology.
- •Known allergy to polyvinylchloride or medicinal liquid paraffin.
- •Ongoing treatment with drugs indicated for respiratory or cardiac disorders.
- •Any disease, condition (medical or surgical) including allergic, immunological and gastro-intestinal conditions and/or chronic medications which, in the opinion of the investigator, might compromise the study results, or would place the subject at increased risk.
- •Vital signs with clinically significant deviations that would make the subject unsuitable for the study, as judged by the investigator.
- •Evidence of significant cardiovascular disease defined by the following:
- •New York Heart Association (NYHA) Class III or IV heart failure;
- •Presence of symptomatic coronary artery disease or unstable angina;
- •Persistent arrhythmia requiring chronic pharmacotherapy or implantable device;
- •Clinically significant abnormalities seen on the screening electrocardiogram as assessed by the investigator;
- •Clinically significant deviations in, hematology (including coagulation parameters aPTT and INR) variables, blood chemistry variables or urinalysis as assessed by the investigator.
- •Positive screening test for HIV or hepatitis B or C
- •Positive alcohol breath test at Visit 1 or at Visit
- •Non-smoker since at least six months at time of screening.
- •Is currently implanted with an electrical and/or neurostimulator device, including but not limited to cardiac pacemaker, defibrillator, vagal neurostimulator, deep brain stimulator, spinal stimulator, bone growth stimulator, or cochlear implant.
- •Previously treated with radiation on the face
- •Previous radiation therapy to the head or neck regions
- •Previously treated with an implantable stimulator or any implantable device in the head and / or neck
- •Has a recent or repeated history of syncope.
- •Has a recent or repeated history of seizures.
- •Surgery within the past three months, determined by the PI to be clinically relevant.
- •Strenuous exercise within 2 days of Visit 1 or Visit
- •Women who are pregnant or nursing.
- •Female subjects: unwilling to use adequate contraceptive measures from the signing of the informed consent until end of the study at the follow-up visit.
- •Received study drug in a clinical trial for an investigational drug within the previous 30 days, or 5 half-lives, whichever is longer.
- •Blood donation or loss of whole blood exceeding 100 mL within 30 days from screening or plasma within 14 days from screening.
- •Excessive intake of alcohol, defined as an average daily intake of greater than three units, or a maximum weekly intake of greater than 21 units ((three units equal 250 ml of 12% alcohol by unit wine).
- •Concurrent condition or risk of non-compliance that, in the investigator's opinion, may affect the interpretation of performance or safety data or which otherwise contraindicates participation in a clinical investigation.
结局指标
主要结局
Change in ECG variables
时间窗: Approximately 1 hour prior to treatment initiation to 3 hours post treatment termination
ECG variables as documented on continuous recording include heart rate, heart rate variability,T-wave morphology, and occurrence of arrhythmias
Change in Vital signs
时间窗: Approximately 1 hour prior to treatment initiation, right before treatment initiation, 10 min after treatment termination and 3 hours after treatment termination
Vital signs measurements include blood pressure, pulse and respiratory rate
次要结局
未报告次要终点
研究者
相似试验
已完成
4 期
An open label study to assess the efficacy, safety and tolerability of pyronaridine-artesunate in the treatment of malaria infection caused by single or mixed species of Plasmodium falciparum, P. vivax, or P. malariae in VietnamMalariaACTRN12618001429246S Naval Medical Research Center-Asia and US Naval Medical Research Unit - Two110
招募中
2 期
Clinical study of Cannabidiol in children and adolescents with Developmental and Epileptic EncephalopathyDevelopmental disabilityNeurological - EpilepsyNeurological - Other neurological disordersEpilepsyACTRN12618000516280Zynerba Pharmaceuticals Pty Ltd55
进行中（未招募）
不适用
An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizurePartial Onset Epilepsy SeizuresEUCTR2007-001801-99-HUJanssen-Cilag International N.V.510
进行中（未招募）
1 期
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or without Dasabuvir and with Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults with Successfully Treated Early Stage Hepatocellular CarcinomaEUCTR2015-001049-10-ESAbbVie Deutschland GmbH & Co. KG3
尚未招募
4 期
To evaluate the effect of PentaSure fibersupplementation in the management of Functional Constipation among ChildreCTRI/2023/10/058430Hexagon Nutrition Limited